Haemophilia B
Adult: For the prevention and control of bleeding: Dosage is individualised based on the severity of factor IX deficiency, extent and location of bleeding, and patient's clinical response. Recommended target factor IX concentrations: Mild to moderate haemorrhage: Increase to 20-30%. Major haemorrhage or surgeries: Increase to 30-50%. Doses are given via IV inj or infusion at a rate not exceeding 10 mL/min. Refer to specific product guidelines for further instructions on dosage and administration.